Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease ... ALS has a significant impact due to its fatal nature and lack of a definitive cure. The ALS treatment market is expected to ...

Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Amyotrophic Lateral Sclerosis.

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...